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Immune checkpoint inhibitors (ICIs) directed against 
programmed cell death protein 1(PD-1) and its ligand 
(PD-L1) have rapidly changed non-small cell lung cancer 
(NSCLC) treatment paradigms, leading to unprecedented 
results, both in metastatic and locally advanced disease. 
The idea that the immune system could be not just a 
guardian, but also an active soldier against tumour has 
been long perceived, since the use of vaccines in the 19th 
century (1). Currently available monoclonal antibodies 
are able to remove inhibitory signals from immune 
system, especially cytotoxic T-cells. While anti cytotoxic 
T-lymphocyte antigen A (CTLA-4) directed drugs mainly 
act during T-cell priming, anti PD-1/PD-L1 agents bind 
their therapeutic targets at the tumour site. The promise 
of such approach consists of re-educating patients own 
immune system to react against cancer cells for a long 
time. The recent publication of the 5-year overall survival 
(OS) results from the KEYNOTE-001 trial by Garon and 
colleagues on the Journal of Clinical Oncology suggests that 
such ambitious goal may be really reached, at least for some 
patients (2). This study was a multi-cohort phase I trial 
enrolling patients with advanced solid tumours, including 
NSCLC. Among them, the treatment-naïve cohort enrolled 
patients who had not received previous therapy (except for 
adjuvant chemotherapy at least 1 year before enrolment), 
without epidermal growth factor receptor (EGFR) 
activating mutations or anaplastic lymphoma kinase (ALK) 
rearrangements, and a PD-L1 tumour proportion score 
(TPS) of 1% or more detected with 22C3 clone. The other 
cohorts included advanced NSCLC patients progressing 
after at least one line of therapy for their metastatic disease. 
The main exclusion criteria were: central nervous system 
metastases (unless clinically stable for at least 4 weeks after 
local treatment) and autoimmune disease requiring systemic 
corticosteroids and/or immunosuppressive drugs. Initially, 
Pembrolizumab was administered intravenously at a dose 
of 2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks. 
In April 2006, a protocol amendment shifted patients to 
200 mg every 3 weeks flat dose schedule and allowed 
patients, who achieved disease control after 24 months 
of treatment, to discontinue pembrolizumab, resuming 
treatment in case of disease recurrence/progression. The 
study primary end-point was objective response rate 
(ORR) by independent central review using Response 
Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 
Investigator-assessed ORR using immune related response 
criteria (irRECIST), OS and duration of response (DOR) 
were secondary end-points. The study enrolled 550 patients, 
449 of them previously treated and approximately 80% with 
non-squamous histology. In the treatment naïve cohort, 
60 patients (59%) were male, 57 (56%) with ECOG PS of 
1, and most (90, 89%) current or former smokers. When 
looking at pre-treated patients, 229 (51%) were male, 299 
(67%) had ECOG PS of 1, 324 (72%) current or former 
smokers, and 82 patients (18%) had EGFR mutations or 
ALK rearrangements. At a median follow-up of 60.6 months 
212
Bironzo et al. KEYNOTE-001: another step from care to cure?
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2019;7(Suppl 6):S212 | http://dx.doi.org/10.21037/atm.2019.08.91
Page 2 of 3
(range, 51.8–77.9), the median treatment duration was 
3.3 months (range, 1 day to 75.9 months), with 100 patients 
still alive. The median OS was 22.3 months (95% CI, 
17.1–32.3) for previously untreated and 10.5 months (95% 
CI, 8.6–13.2) for pre-treated patients, with an estimated 5 
years OS of 23.2% and 15.5%, respectively. The ORR by 
irRECIST was 41.6% (95% CI, 31.9–51.8) and 22.9% (95% 
CI, 19.1–27.1) for treatment-naïve and previously treated 
patients, respectively, while a lower percentage was evident 
using RECIST 1.1 (24.8% and 18.0%, respectively). 
Notably, the median time to response was 2.1 months in all 
groups and the median DOR was 16.8 months in untreated 
patients (range, 2.1–55.7) and 38.9 months among the 
others (range, 1.0–71.8). When stratifying patients using 
PD-L1 expression levels, a TPS of 50% or greater was 
associated with increased OS so that the median OS was 
35.4 months (n=27; 95% CI, 20.3–63.5) in treatment naïve 
patients, with a 5-year rate of 29.6% as compared to 19.5 
months (n=52; 95% CI, 10.7–26.3) and 15.7% in those with 
TPS between 1% and 49%. Using the same cut-off for the 
other cohorts, the median OS was 15.4 months (n=138; 
95% CI, 10.6–18.8) for high PD-L1 patients as compared 
to 8.5 (n=168; 95% CI, 6.0–12.6) and 8.6 months (n=90; 
95% CI, 5.5–10.6) for those with TPS of 1% to 49% and 
less than 1%, respectively. In these subgroups the 5-year OS 
rate were 25.0%, 12.6%, and 3.5%, respectively. 
These long-term results are in line with those reported 
for another anti-PD-1 agent, nivolumab, in the phase I 
CA209-003 trial (3). In this study, among the 129 pre-
treated metastatic NSCLC patients, the ORR (by RECIST 
1.0) was 17.1%, with a DCR of 41.9% and a median DOR 
of 19.1 months (8.7 to not estimable). With a minimum 
follow-up of 58.3 months, the median OS was 9.9 months 
(95% CI, 7.8–12.4), while the 5-year survival rate was 
15.6% (95% CI, 9.6–22.9). The consistency of survival 
outcomes among these two different studies suggests, once 
again, that phase I clinical trials provide reliable efficacy 
results, which should be carefully considered in the further 
steps of clinical investigation. 
However, how can we put these data in the current 
treatment scenario? Starting from the publication of the 
KEYNOTE-024 trial, demonstrating a clear survival 
benefit of pembrolizumab as compared to platinum 
doublets in treatment naïve advanced NSCLC patients 
with PD-L1 TPS of 50% or more (4), and then moving to 
KEYNOTE-189 and KEYNOTE-407 studies, showing 
that upfront immune-chemotherapy combination was 
superior to chemotherapy alone (5,6), regardless of tumour 
histotype and PD-L1 expression levels, ICIs are being 
moved in the front-line setting worldwide. Moreover, the 
recent approvals by the U.S. Food and Drug Administration 
(FDA) of pembrolizumab monotherapy in treatment 
naïve advanced NSCLC patients with a PD-L1 TPS of 
1% or more based on KEYNOTE-042 results (7), and 
of atezolizumab (anti-PD-L1 mAb) in combination with 
carboplatin, paclitaxel and bevacizumab irrespective of 
PD-L1 levels in non-squamous histology (8), further 
complicated the already crowded landscape. At the first 
sight, updated results from KEYNOTE-001 seems of 
minor interest and look just as another piece of the mosaic. 
It appears obvious that the effects of single agent ICIs could 
not be straightforward transposed in naïve patients receiving 
combination treatments (accounting for the majority of 
patients, nowadays) as the effects of cytotoxic drugs on 
both tumour cells and immune system must be taken into 
account. However, some hints from this publication could 
enlarge our current knowledge. First, this update clearly 
demonstrates that using ICIs during advanced NSCLC 
patient treatment journey lead to unprecedented survivals, 
at least in non-oncogene-addicted population. The evidence 
that 15% of previously treated patients, and about 30% of 
naive with PD-L1 TPS of 50% or greater, could survive 
at 5 years from first ICI dose administration is something 
judged impossible few years ago. At the same time, also 
safety doesn’t seem an issue, even as time goes on. With 
this long follow-up, only 13% of grade 3 to 5 treatment-
related adverse events (trAEs) have been reported, requiring 
treatment discontinuation only in 31 patients (6%), six of 
them with ongoing response. Focusing on immune-related 
AEs (irAEs), the incidence was low (17%, with only 4% of 
grade 3 to 5), with no difference at 3 or 5 years of follow-up. 
Interestingly, as already reported by Topalian and colleagues 
for nivolumab (3), the occurrence of irAEs is a strong 
predictive factor of disease response and survival benefit 
even with pembrolizumab. These information are of great 
value in supporting daily clinical practice, as oncologists 
can safely decide to stop treatment when irAEs occur, 
even in those patients who are gaining benefit from ICIs. 
This marks a real paradigm shift as compared to the classic 
approach with chemotherapy. Third, this study confirms 
that PD-L1 expression, even if still far from being a sturdy 
predictor of efficacy, remains a reliable stratification factor. 
Unfortunately, no other clinical, laboratory, or molecular 
biomarkers have been reported by the Authors. Recent literature 
suggests that simple clinical variables such as ECOG PS, the 
presence of liver or bone metastases (3), or Lung Immune 
Annals of Translational Medicine, Vol 7, Suppl 6 September 2019 Page 3 of 3
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2019;7(Suppl 6):S212 | http://dx.doi.org/10.21037/atm.2019.08.91
Prognostic Index score (9) as well as (STK11/LKB1 genes 
mutations or other rare oncogenic alterations) (10,11) 
could further dissect this apparently homogenous group. 
Moreover, such data could be of priceless value especially in 
patients achieving the longest benefit from ICIs.
In conclusion, the updated results of KEYNOTE-001 
confirm long-term efficacy of single agent ICI in pre-treated 
patients with metastatic disease, and show for the first time 
unprecedent 5-year survival associated to the upfront use of 
pembrolizumab in high PD-L1 expressors, laying another 
stone on the road from care to cure for advanced NSCLC 
patients. 
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